Application of polydocanol in construction of animal model of retinal vein occlusion and construction method of animal model of retinal vein occlusion
A stable retinal vein occlusion model was established by injecting polidocanol foam into the retinal vein, which solved the problems of short recanalization time and retinal damage in existing models, and provided a reliable animal model suitable for Bama miniature pigs for drug validation.
Patent Information
- Application Number
- CN202411528851.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-30
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2044-10-30
AI Technical Summary
Existing animal models of retinal vein occlusion have short recanalization times and are often accompanied by damage to retinal pigment epithelial cells and photoreceptor cells, lacking stability and models similar to human diseases.
A retinal vein occlusion model was established by mixing polydextrose with air to form a dense foam, which was then injected into the retinal vein through a 48G needle. The properties of the foam sclerosing agent were then used to block the blood vessel.
A stable retinal vein occlusion model can be established with a single injection. It is suitable for Bama miniature pigs. The model is similar in size to the human eyeball, making it suitable for verifying drug targets and the mechanism of action of candidate drugs, without damaging the retinal structure.
Smart Images

Figure CN119033810A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the use of polidocanol in constructing an animal model of retinal vein occlusion and a method for constructing an animal model of retinal vein occlusion, belonging to the field of medical technology. Background Art
[0002] Retinal vein occlusion (RVO) is the second most common vascular disease causing vision loss, second only to diabetic retinopathy. In the early stages of the disease, the affected veins are often tortuous, congested, dilated, retinal hemorrhage and edema, and large areas of non-perfused areas are formed. In the later stages, complications such as cystoid macular edema, vitreous hemorrhage, and neovascular glaucoma often lead to a sharp decline in vision or even blindness. Clinically, according to the site of vascular occlusion, RVO can be divided into central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO). The pathogenesis of RVO is not yet fully understood, and there is no definite drug for the treatment of intravascular thrombosis. At present, the commonly used treatment methods in ophthalmology are mainly symptomatic treatments (such as retinal laser photocoagulation, vitrectomy, intravitreal injection of hormones or anti-vascular endothelial growth factor drugs, etc.), but these treatments can cause retinal damage and increase the risk of endophthalmitis, cataracts, glaucoma, etc.
[0003] The existing methods for establishing RVO models mainly include the following: vascular ligation, diathermy, intravitreal injection of endothelin-1 (ET-1), laser photocoagulation to block retinal veins, and intravenous injection of photosensitizing drugs combined with laser photocoagulation. The vascular ligation method causes poor retinal venous return by burning and ligating the central retinal vein, and the blood vessels are recanalized for a long time. However, the modeling process is complicated, technically difficult, destructive, and prone to infection and death of animals after surgery. The diathermy method can accurately locate blood vessels, cause vasoconstriction and damage to blood vessels through electric heating, and instantly block blood vessels. However, this method uses electric heating energy to block blood vessels and destroy vascular endothelium, which is different from the formation mechanism of human RVO. Its guiding significance for clinical practice needs further study. Endothelin-1 is a powerful vasoconstrictor peptide. Different concentrations of ET-1 injected into the vitreous cavity induce different vascular responses. RVO caused by appropriate concentrations of ET-1 is caused by severe vascular spasm and is only suitable for the study of electrophysiological changes in monkeys with retinal ischemia. Laser photocoagulation to block retinal veins is a non-invasive procedure. The laser is shot directly at the blood vessels to be blocked through a three-sided mirror, and the irradiated blood vessels are blocked by heat energy. However, the recanalization rate of blocked blood vessels is high and the recanalization time is early. Repeated photocoagulation is required, which can easily cause severe thermal damage to retinal pigment epithelial cells and photoreceptor cells, and is often accompanied by vitreous hemorrhage caused by vascular wall damage, which affects fundus observation. The intravenous injection of photosensitizers combined with laser photocoagulation is to inject photosensitizers into the veins, and then irradiate the retinal blood vessels to be blocked with laser. Under the combined action of photosensitizers and irradiation lasers, an RVO model is formed. This method forms a model immediately, and the blocked blood vessels are recanalized in about 7 days. However, the damage of laser photocoagulation to the eyeball is related to the amount of fundus pigment. The higher the pigment content of the irradiated tissue, the stronger the absorption of light energy, and the more susceptible to laser damage. Due to the shielding effect of non-pigmented tissue in the fundus of non-pigmented animals, the choroidal blood vessels can directly absorb external laser energy to produce photochemical reactions, resulting in choroidal blood vessel blockage.
[0004] In general, the existing RVO model has a short vascular recanalization time and cannot be maintained for a long time. In addition, it may cause damage to the retinal pigment epithelial cells and photoreceptor cells in addition to vascular occlusion. Therefore, based on the above situation, it is very necessary to establish an animal model with good reproducibility and that can present a pathological process similar to that of the disease to conduct research on etiology, pathology and therapeutics.
[0005] Application number: CN202011557373.0, invention name: Method for constructing a novel mouse model of retinal vein occlusion, which relates to a method for constructing a novel mouse model of retinal vein occlusion. The method for constructing the novel mouse model of retinal vein occlusion includes the steps of injecting a Muller cell metabolic inhibitor into the vitreous body after intervening the mouse with a photodynamic method. The retinal vein occlusion mouse model prepared by this construction method is stable and can achieve persistent retinal edema, which is convenient for verifying drug targets and the mechanism of action of candidate drugs after injection. This method requires two operations to establish the model, and the steps are relatively complicated. At the same time, the applicable animal species is mice, and the retinal structure of mice is still quite different from that of humans.
[0006] Selecting appropriate experimental animals and building animal models close to human diseases is the basis and premise of medical research. At present, the choice of experimental animals is mainly mammals, among which rodents are the most used, but there is still a certain gap between them and humans in terms of tissue structure, metabolic characteristics, pathogenesis, etc. In recent years, more and more scholars at home and abroad have begun to use miniature pigs to build disease models. Due to their unique advantages in physiological and biochemical indicators, anatomical structure, dietary characteristics, drug metabolism and disease development, they are considered to be ideal animal species for medical research. At present, Bama miniature pigs have been used in the fields of cardiovascular, skin plastic surgery, endocrine and metabolism, digestion, oral medicine, and organ transplantation. There are few studies on the use of miniature pigs in the field of ophthalmic diseases. (Zou Disha, et al., Research Progress of Bama Miniature Pig Animal Model in the Medical Field, Chinese Journal of Animal Husbandry and Veterinary Medicine 2017, 44 (4): 1128-1134).
[0007] Clinically, foam sclerosant is a safe and effective drug for the treatment of vascular diseases, mainly used to treat varicose veins, hemangiomas and other diseases. Polydocanol injection is a foam sclerosant, which is clinically used to treat central veins, reticular veins and small varicose veins of spider veins. Polydocanol mainly destroys the surfactant molecules on the cell membrane of vascular endothelial cells, destroys the cell membrane structure, lyses vascular endothelial cells, causes vascular fibrosis, occlusion and thrombosis, thereby achieving the purpose of clinical treatment of varicose veins. Varicose veins and retinal vein occlusion are two different diseases, which affect different parts of the vascular system. Varicose veins mainly affect the superficial veins of the lower limbs, while retinal vein occlusion affects the retinal blood vessels of the eyes. There are currently no relevant literature reports on the use of polidocanol injection for the construction of an animal model of retinal vein occlusion. Summary of the invention
[0008] The present invention provides a new animal model of retinal vein occlusion, which is the use of polidocanol in constructing an animal model of retinal vein occlusion and a method for constructing an animal model of retinal vein occlusion.
[0009] The present invention provides the use of polidocanol in constructing an animal model of retinal vein occlusion.
[0010] Wherein, the animal is a mammal.
[0011] Wherein, the polidocanol is applied to the retinal vein, and the application amount is: 0.4-0.5 mg / eye / time.
[0012] The present invention provides a method for constructing an animal model of retinal vein occlusion, which comprises the following steps: a. Preparation of modeling agent: Mix polidocanol injection with air and repeatedly beat to form dense foam, wherein the volume ratio of polidocanol injection to air is 1:3-4 (v / v), wherein the concentration of polidocanol injection is 1% w / v, and after mixing with air, each ml contains 2-2.5 mg of polidocanol; b. Apply the modeling agent into the retinal vein to prepare a retinal vein occlusion animal model.
[0013] Wherein, the animal is a mammal.
[0014] Wherein, the animal is Bama miniature pig.
[0015] Wherein, the volume ratio of the polydocanol injection to air is: 1:3 (v / v).
[0016] Among them, the device for preparing the modeling agent is: containing: two threaded syringes and a three-way valve; one threaded syringe draws out the polydocanol injection solution, and the other threaded syringe draws out the air, the two threaded syringes are respectively connected to the two ends of the three-way valve, the three-way valve switch is turned to make the two ends of the syringes connected connected, and the syringes at both ends are pushed successively to fully mix the polydocanol injection solution and the air, and quickly pumped until dense foam is formed.
[0017] The present invention also provides use of the animal model of retinal vein occlusion constructed by the construction method in screening drugs for preventing and / or treating retinal vein occlusion.
[0018] The present invention provides a method for screening candidate drugs for preventing and / or treating retinal vein occlusion, wherein the candidate drugs are applied to the animal model of retinal vein occlusion constructed by the construction method.
[0019] Clinically, foam sclerosant is a safe and effective drug for treating vascular diseases, mainly used to treat varicose veins and other diseases. Foam sclerosant is a liquid preparation that can form dense foam after mixing with a certain proportion of air. When injected into the vein, the dense foam will not flow back with the blood, and will stimulate and damage vascular endothelial cells at the injection site, thereby blocking blood flow back. Therefore, with the help of this characteristic of the foam sclerosant, the present invention uses a 48G needle to inject it into the retinal vein, in order to block the blood vessels to form a stable and long-lasting RVO model, providing a new and reliable animal model for preclinical research of related drugs.
[0020] The beneficial effects of the present invention are: The present invention can establish a relatively stable model with only one injection, and the drugs and instruments used are all available on the market. The applicable species is the Bama miniature pig, whose eyeball size is close to that of humans, and there is a visual stripe area on the retina (i.e., a visually sensitive area that corresponds to the macular area of the human retina). Therefore, it can be better used to verify drug targets and the mechanism of action of candidate drugs after injection. BRIEF DESCRIPTION OF THE DRAWINGS
[0021] Figure 1 A device for preparing a modeling agent; Figure 2 This is the expansion of the distal end of the retinal vein after the injection of polidocanol injection (the red box is the injected vein, and the blood vessel can be seen to be significantly dilated and thickened); Figure 3 Fundus photography of miniature pigs in the 0.5% polidocanol injection group (black arrows point to retinal hemorrhages; red arrows point to tortuous and dilated retinal blood vessels; yellow arrows point to large retinal hemorrhages; green arrows point to retinal atrophy areas); Figure 4 This is the fundus angiography of miniature pigs in the 0.5% polidocanol injection group (the black shadow indicated by the red arrow is the fluorescence shielding caused by retinal hemorrhage; the yellow arrow indicates the high fluorescence leakage of the vascular terminal; the green arrow indicates the retinal atrophy focus and the local retinal high fluorescence area); Figure 5 This is the OCT image of the retina of miniature pigs in the 0.5% polidocanol injection group (the area indicated by the red arrow is subretinal fluid; the area indicated by the yellow arrow shows medium-high reflective signals, indicating retinal hemorrhage; the area indicated by the green arrow is the area of retinal atrophy); Figure 6 This is the histopathological examination picture of the retina of miniature pigs in the 0.5% polidocanol injection group (the atrophy of the lower retina in the black box area); Figure 7Fundus photography of miniature pigs in the 1% polidocanol injection group (black arrows indicate tortuosity and dilation of retinal blood vessels; red arrows indicate retinal hemorrhage); Figure 8 This is the fundus angiography of miniature pigs in the 1% polidocanol injection group (the black shadow indicated by the red arrow is the fluorescence shielding caused by retinal hemorrhage; the yellow arrow indicates the high fluorescence leakage at the end of the blood vessel); Fig. 9 This is the OCT image of the miniature pig retina in the 1% polidocanol injection group (the red arrow points to retinal neuroepithelial edema; the yellow arrow points to retinal hemorrhage; the green arrow points to retinal atrophy); Fig.10 This is the retinal tissue pathological examination picture of miniature pigs in the 1% polidocanol injection group (where A represents retinal vascular dilation and hemorrhage / congestion, and B represents retinal atrophy (the black box area represents retinal atrophy)); Fig.11 Fundus photography, FFA and retinal OCT images of miniature pigs in the 3% polidocanol injection group (A is fundus photography, B is fundus fluorescein angiography, and C is retinal OCT image); Fig.12 This is the HE staining image of the retina in the 3% polidocanol injection group (A, the black arrows indicate retinal vascular dilation and hemorrhage / congestion; B, the black box area indicates retinal atrophy; C, lens degeneration). DETAILED DESCRIPTION
[0022] Example 1 Method for constructing an animal model of retinal vein occlusion of the present invention This method was performed on Bama miniature pigs and has been approved by the Experimental Animal Use and Management Committee of Chengdu Huaxi Haiqi Pharmaceutical Technology Co., Ltd. The foam sclerosant used was polidocanol injection with concentrations of 0.5%, 1%, and 3%, respectively, that is, 0.5g, 1g, and 3g of polidocanol per 100mL.
[0023] Bama miniature pigs were divided into three groups, namely, 0.5% polidocanol injection group, 1% polidocanol injection group and 3% polidocanol injection group.
[0024] Before modeling, Bama miniature pigs were instilled with compound tropicamide eye drops to dilate the pupils, and anesthetized with 5 mg / kg of Shutai 50 + 2 mg / kg of xylazine + 4 mg / kg of ketamine hydrochloride (22.73 mg / mL of Shutai 50 + 9.09 mg / mL of xylazine + 18.18 mg / mL of ketamine hydrochloride, 0.22 mL / kg intramuscular injection). After anesthesia, the animals were intubated and maintained with a ventilator. Oxybuprocaine eye drops were dripped into both eyes for surface anesthesia from time to time.
[0025] The specific modeling method is as follows: After using povidone-iodine to disinfect the eye skin, eyelid margin and conjunctival sac, use a scleral tunnel needle to puncture the eyeball at the nasal and temporal ciliary body flat parts to establish a scleral tunnel. Use a threaded syringe and a three-way valve to mix the polidocanol injection and air in a ratio of 1:3 (v / v) and repeatedly push and beat to form dense foam (use two threaded syringes, one to extract an appropriate amount of polidocanol injection, and the other threaded syringe to extract air 3 times the volume of polidocanol injection. Connect the two threaded syringes to the two ends of the three-way valve respectively, turn the three-way valve switch to connect the two ends of the syringe, push the syringes at both ends successively, mix the polidocanol injection and air fully, and quickly pump until dense foam is formed). An appropriate amount of modeling agent mixed with air was extracted, and an illumination fiber was inserted into one side of the scleral tunnel, and a 48G injection needle was inserted into the other side. The push injection system of the phacovitrectomy machine (Constellation, Alcon) was used to inject the sclerosant into the retinal vein near the edge of the optic disc toward the distal end of the retinal vein (injection volume was 200 μL). The dosage of polidocanol was 0.4-0.5 mg / eye / time. After the injection, the illumination fiber was used to press the injection point (continuous compression for about 5 minutes). After the operation was completed, the fiber and injection needle were withdrawn, the scleral tunnel needle was removed, and ofloxacin eye ointment was applied to prevent infection.
[0026] The device for preparing the modeling agent is as follows Figure 1 shown.
[0027] Among them, 1 is syringe 1, 2 is syringe 2, and 3 is a three-way valve. The three-way valve can be an ordinary ball valve.
[0028] The specific usage of the device is: Use threaded syringe 1 to extract the polidocanol injection solution, and another threaded syringe 2 to extract the air. Connect the two threaded syringes to the two ends of the three-way valve respectively, turn the three-way valve switch to connect the two ends of the syringes, push the syringes at both ends successively to fully mix the polidocanol injection solution and the air, and quickly pump until dense foam is formed. When repeatedly pumping and mixing, turn the three-way valve to connect the two ends of the syringe.
[0029] The purpose of the above-mentioned device is bubbling, which is the process of introducing gas (usually air) into liquid. Therefore, the present invention is not limited to the above-mentioned device, and the currently commonly used stirring method, mechanical bubbling method (bubbler, bubbling pump), gas injection method, vacuum bubbling method, etc. can all be applied.
[0030] Example 2 Detection of the animal model of retinal vein occlusion prepared by the present invention and screening test of different doses of polidocanol injection 1. Retinal optical coherence tomography (OCT) Examinations were performed once before administration and on the 2nd, 7th, 14th and 28th days after administration. After anesthesia of the Bama miniature pigs (anesthesia method was the same as in Example 1), compound tropicamide eye drops were used to dilate the pupil (eye drops, 1-2 drops / eye), and a laser ophthalmological diagnostic instrument (SpectralisOCT, Heidelberg, Germany) was used to perform OCT rapid linear scanning of the pig fundus retina to display the structure of each layer of the retina.
[0031] 2. Fundus photography and fluorescein angiography (FFA) Examinations were performed once before administration and on the 2nd, 7th, 14th and 28th days after administration. After anesthesia of the Bama miniature pigs (anesthesia method was the same as in Example 1), the mydriasis was performed with compound tropicamide eye drops (eye drops, 1-2 drops / eye), and fundus photography was performed with an ophthalmic laser diagnostic instrument (SpectralisHRA, Heidelberg, Germany). Fluorescein sodium injection (0.1 mL / kg) was rapidly injected from the pig's ear vein to photograph the fundus images in the early (within 1 min) and late (after 5 min) after contrast imaging.
[0032] 3. Histopathological examination On the 28th day after administration, the Bama miniature pigs were anesthetized according to their body weight (anesthesia method was the same as in Example 1), and euthanized by bleeding through the abdominal aorta. After the eyeballs were removed, they were fixed in a modified Davidson's fixative, and paraffin sections were made according to the standard histopathological technical operation, and hematoxylin-eosin (HE) staining was performed, and microscopic examination was performed.
[0033] A few minutes after the injection of polidocanol into the retinal vein, the distal end of the vein was significantly dilated, indicating that the vascular endothelium was damaged and the blood vessel was gradually blocked. Figure 2 .
[0034] Fundus photography of miniature pigs in the 0.5% polidocanol injection group on the second day after injection ( Figure 3 ) Scattered hemorrhages can be seen around the injected vein and the retinal area where the vein is responsible for venous return, and the vein is tortuous and dilated. FFA examination ( Figure 4 ) Local fluorescence shielding and high fluorescence leakage at the end of blood vessels can be seen. On the 7th to 14th day after injection, fundus photography can show large retinal hemorrhages, the degree of venous tortuosity and dilation is reduced, and FFA can show large retinal hemorrhages shielding fluorescence. On the 28th day after injection, retinal hemorrhages are gradually absorbed, atrophy foci can be seen in the retina, local retinal high fluorescence can be seen in FFA, and no fluorescence leakage is seen at the end of blood vessels. On the 2nd day after drug injection, OCT examination ( Figure 5) Subretinal fluid was observed in the injection area, which was caused by the injection of the drug into the subretina. Retinal hemorrhage was observed on OCT 7 days after injection. The retina in the hemorrhage area gradually atrophied 14 to 28 days after administration, and no obvious retinal edema was observed at the end of observation. Histopathological examination on the 28th day after injection showed retinal atrophy in the injected eye ( Figure 6 ).
[0035] On the second day after injection, fundus photography of the miniature pigs in the 1% polidocanol injection group showed scattered bleeding spots and large hemorrhages around the injected vein and the retinal area where the vein was responsible for venous return. The veins were tortuous and dilated. In the early stage of FFA examination, large areas of fluorescence obscuration were observed, and high fluorescence leakage of vascular terminals was observed in the late stage ( Figure 7 , Figure 8 ). By the 28th day after injection, retinal hemorrhage was gradually absorbed, and FFA still showed fluorescence shielding and high fluorescence. On the second day after drug injection, OCT images showed low reflection signals between the retinal neuroepithelial layers, indicating retinal neuroepithelial edema. At the same time, local retinal thickening and enhanced reflection signals indicated retinal hemorrhage. By the 14th day after injection, the degree of retinal neuroepithelial edema and hemorrhage gradually decreased. On the 28th day after injection, the thickness of the retinal neuroepithelial layer decreased significantly, and the structures of the various layers of the retina were disordered and unrecognizable, indicating retinal atrophy ( Fig. 9 Histopathological examination revealed retinal vascular dilation, hemorrhage / congestion, and retinal atrophy in the injected eye ( Fig.10 ).
[0036] Fundus photography, FFA and retinal OCT examinations failed to obtain fundus images of the miniature pigs in the 3% polidocanol injection group on days 2, 7, 14 and 28 after injection. Slit lamp examination revealed large retinal hemorrhages on day 2 after administration, and large white deposits appeared in the posterior capsule of the lens on days 7 to 28 after administration, which appeared ground glass and made it impossible to observe the fundus (see Fig.11 ).
[0037] In the 3% polidocanol injection group, vascular dilation, hemorrhage / congestion, retinal atrophy, and lens degeneration were observed in the injected eye. Fig.12 ).
[0038] The experimental results of the above-mentioned different concentrations of polydocanol injection showed that no obvious retinal edema occurred at the 0.5% concentration, edema occurred at the 1% concentration and could last for 2 weeks, and the 3% concentration caused more severe damage and the fundus could not be observed after injection, so the 1% concentration was the best.
[0039] In summary, injection of 1% polidocanol injection into the retinal vein using a 48G injection needle can significantly induce retinal vein occlusion and retinal edema formation, which lasts for at least two weeks and can provide a new animal model for the pharmacodynamic study of related drugs.
Claims
1. Use of polidocanol in constructing an animal model of retinal vein occlusion.
2. The use according to claim 1, Features: The animals are mammals.
3. The use according to claim 1 or 2, Features: The polidocanol is applied to the retinal vein in an amount of 0.4-0.5 mg / eye / time.
4. A method for constructing an animal model of retinal vein occlusion, Features: It includes the following steps: a. Preparation of modeling agent: Mix polidocanol injection with air and repeatedly beat to form dense foam, wherein the volume ratio of polidocanol injection to air is 1:3-4, wherein the concentration of polidocanol injection is 1% w / v, and after mixing with air, each ml contains 2-2.5 mg of polidocanol; b. Apply the modeling agent into the retinal vein to prepare a retinal vein occlusion animal model.
5. The method for constructing an animal model of retinal vein occlusion according to claim 4, Features: The animals are mammals.
6. The method for constructing an animal model of retinal vein occlusion according to claim 5, Features: The animal is a Bama miniature pig.
7. The method for constructing an animal model of retinal vein occlusion according to claim 4, Features: The volume ratio of the polydocanol injection to air is 1:
3.
8. The method for constructing an animal model of retinal vein occlusion according to any one of claims 4 to 7, Features: The device for preparing the modeling agent is as follows: it contains two threaded syringes and a three-way valve; one threaded syringe draws out the polydocanol injection solution, and the other threaded syringe draws out the air. The two threaded syringes are respectively connected to the two ends of the three-way valve, and the three-way valve switch is turned to connect the two ends of the syringes, and the syringes at both ends are pushed successively to fully mix the polydocanol injection solution and the air, and then quickly pumped until dense foam is formed.
9. Use of the animal model of retinal vein occlusion constructed by the construction method according to any one of claims 4 to 8 in screening drugs for preventing and / or treating retinal vein occlusion.
10. A method for screening candidate drugs for preventing and / or treating retinal vein occlusion, Features: The candidate drug is administered to the animal model of retinal vein occlusion constructed by the construction method according to any one of claims 4 to 8.
Citation Information
Patent Citations
Novel retinal vein obstruction mouse model construction method
CN112568187A
Application of lauromacrogol in preparation of chronic intraocular hypertension animal model and animal model
CN113273546A
Application of polydocanol in preparation of medicine for treating lymphatic leakage
CN118697761A
Foaming injection device for polydocosyl alcohol injection
CN211022901U
Sclerotherapy for varicose veins
WO2009100435A2
